DermaVir®
HIV/AIDS (Therapeutic Vaccine)
Pre-clinical/Clinical (Phase not specified)Active
Key Facts
Indication
HIV/AIDS (Therapeutic Vaccine)
Phase
Pre-clinical/Clinical (Phase not specified)
Status
Active
Company
About Genetic Immunity
Genetic Immunity is a private, pre-revenue biotech developing a proprietary plasmid DNA-based therapeutic vaccine platform. Its lead candidate, DermaVir®, is designed to boost cytotoxic T-cell responses to target and kill HIV-infected cells, positioning it as a potential functional cure component. The company leverages a multidisciplinary team and international collaborations, with core competencies spanning research, development, and GMP-compliant production planning for clinical batches in the EU.
View full company profile